Product Description
Bridge Biotherapeutics, Inc. is developing BBT-176 as a treatment for Advanced Non-Small Cell Lung Cancer (NSCLC). (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04820023)
Mechanisms of Action: EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bridge Biotherapeutics, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Small Cell Lung Cancer|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04820023 |
BBT176-ONC-001 | P2 |
Terminated |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
2023-11-29 |
24% |
2025-06-07 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/29/2024 |
PubMed |
What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors. |
|
08/15/2023 |
PubMed |
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer. |
|
07/11/2023 |
News Article |
Bridge Biotherapeutics Joins PROLIFIC, the Prognostic Lung Fibrosis Consortium |
|
06/02/2023 |
News Article |
Bridge Biotherapeutics to Present Tuesday at the BIO International Convention |
|
05/29/2023 |
News Article |
Bridge Biotherapeutics to Present at the 2023 BIO International Convention |
|
04/23/2023 |
News Article |
Bridge Biotherapeutics Receives FDA Authorization to Proceed with the First-in-Human Study of BBT-207, a 4th generation EGFR TKI |